Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update

Acrivon Therapeutics, Inc. (NASDAQ:ACRVGet Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 484,000 shares, a growth of 22.7% from the February 29th total of 394,600 shares. Currently, 4.0% of the company’s stock are short sold. Based on an average daily trading volume, of 72,000 shares, the short-interest ratio is currently 6.7 days.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ACRV. New York State Common Retirement Fund bought a new stake in shares of Acrivon Therapeutics during the 1st quarter worth about $28,000. Citigroup Inc. boosted its stake in shares of Acrivon Therapeutics by 1,281.2% during the 2nd quarter. Citigroup Inc. now owns 2,790 shares of the company’s stock worth $36,000 after acquiring an additional 2,588 shares in the last quarter. California State Teachers Retirement System bought a new stake in shares of Acrivon Therapeutics during the 1st quarter worth about $41,000. Wells Fargo & Company MN boosted its stake in shares of Acrivon Therapeutics by 108.1% during the 2nd quarter. Wells Fargo & Company MN now owns 3,305 shares of the company’s stock worth $43,000 after acquiring an additional 1,717 shares in the last quarter. Finally, Barclays PLC bought a new stake in shares of Acrivon Therapeutics during the 4th quarter worth about $47,000. 71.62% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on ACRV shares. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Acrivon Therapeutics in a research report on Thursday. JMP Securities started coverage on Acrivon Therapeutics in a research report on Friday, March 1st. They set a “mkt outperform” rating and a $14.00 price target on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $22.14.

Get Our Latest Stock Analysis on Acrivon Therapeutics

Acrivon Therapeutics Price Performance

Shares of ACRV stock opened at $7.15 on Monday. Acrivon Therapeutics has a fifty-two week low of $3.19 and a fifty-two week high of $14.39. The stock’s 50-day moving average is $4.69 and its two-hundred day moving average is $5.37. The firm has a market cap of $158.66 million, a P/E ratio of -2.62 and a beta of 1.70.

About Acrivon Therapeutics

(Get Free Report)

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

Further Reading

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.